Genomic Health to Present Seven New Studies at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium

Dec 03, 2010, 08:00 ET from Genomic Health, Inc.

REDWOOD CITY, Calif., Dec. 3, 2010 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven studies at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010 at the Henry B. Gonzalez Convention Center.  All of the studies analyze the company's Oncotype DX® breast cancer test, which is a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for women with early-stage breast cancer.

Following are details for each embargoed session (all times are in Central Standard Time):

Friday, December 10



>

Abstract: P2-09-05


Poster Session 2 (Prognostic and Predictive Factors: Response Predictions - Biomarkers and Other Factors): "Risk group selection in primary breast cancer according to ASCO-recommended biomarkers of Oncotype DX and uPA-PAI-1: First experience from prospective multicenter WSG Plan B trial"


Lead Author: T. Degenhardt, MD, West German Study Group


Location: Exhibit Halls A-B


Time: 7 a.m. – 9 a.m.



>

Abstract: P2-09-06


Poster Session 2 (Prognostic and Predictive Factors: Response Predictions - Biomarkers and Other Factors): "Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score® in clinical practice"


Lead Author: John Hornberger, MD, MS, CEO & President, Cedar Associates LLC and Adjunct Professor of Medicine, Stanford University


Location: Exhibit Halls A-B


Time: 7 a.m. – 9 a.m.



>

Abstract: S4-9


General Session 4: "Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the Recurrence Score and a new measure that integrates clinical and pathologic factors with the Recurrence Score"


Presenter: Gong Tang, PhD, Assistant Professor of Biostatistics, University of Pittsburgh and Statistician, the NSABP Biostatistical Center


Location: Exhibit Hall D


Time: 3:15 p.m. – 5:30 p.m.



>

Abstract: P3-10-01


Poster Session 3 (Prognostic and Predictive Factors: Prognostic Factors & Biomarkers-Clinical Testing and Validation): "Quantitative gene expression analysis in a large cohort of estrogen-receptor positive breast cancers: Characterization of the tumor profiles in younger patients (<40 yrs) and in older patients (>70 yrs)"


Lead Author: Steven Shak, MD, Genomic Health


Location: Exhibit Halls A-B


Time: 5:30 p.m. - 7:30 p.m.



>

Abstract: P3-10-12


Poster Session 3 (Prognostic and Predictive Factors: Prognostic Factors & Biomarkers-Clinical Testing and Validation): Pilot Phase of the Randomized Plan B Trial: Prospective Comparison of Molecular Classification, Oncotype DX and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer


Lead Author: Oleg Gluz, MD, West German Study Group


Location: Exhibit Halls A-B


Time: 5:30 p.m. - 7:30 p.m.



>

Abstract: P3-10-13


Poster Session 3 (Prognostic and Predictive Factors: Prognostic Factors & Biomarkers-Clinical Testing and Validation): "Prognostic value of genomic analysis after neoadjuvant chemotherapy for breast cancer"


Lead Author: Erica L. Mayer, MD MPH, Staff Physician, Breast Oncology Center


Dana-Farber Cancer Institute and Instructor in Medicine, Harvard Medical School


Location: Exhibit Halls A-B


Time: 5:30 p.m. - 7:30 p.m.



>

Abstract: P3-10-15


Poster Session 3 (Prognostic and Predictive Factors: Prognostic Factors & Biomarkers-Clinical Testing and Validation): "Quantitative gene expression by RT-PCR in classic and variant forms of lobular carcinoma in estrogen receptor positive invasive breast cancer"


Lead Author: Joseph M. Anderson, MD, Genomic Health


Location: Exhibit Halls A-B


Time: 5:30 p.m. - 7:30 p.m.



About the Oncotype DX® Breast Cancer Test

The Oncotype DX breast cancer test is the first and only multigene expression test to be included in the published guidelines of both the American Society of Clinical Oncology and the National Comprehensive Cancer Network, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive.  Additionally, physicians use Oncotype DX to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes.  Oncotype DX has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology.  Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions.  For more information about Oncotype DX for breast cancer, please visit www.oncotypedx.com or www.untileverywomanknows.com.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions.  In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer.  In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010.  As of September 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 175,000 Oncotype DX tests.  The company was founded in 2000 and is located in Redwood City, California.  For more information, please visit www.genomichealth.com.

NOTE: The Genomic Health logo, Oncotype and Oncotype DX are trademarks or registered trademarks of Genomic Health, Inc.

SOURCE Genomic Health, Inc.



RELATED LINKS

http://www.genomichealth.com